<tei>
    <teiHeader>
        <fileDesc xml:id="_Blauvelt 2021.pdf"/>
    </teiHeader>
    <text xml:lang="en">


        <figure>

            <head>Figure </head>
 
            <label>1</label>

            <head>. </head>
 
            <figDesc>Patient Disposition Through Week 24</figDesc>
        </figure>


        <figure>

            <head>Figure </head>
 
            <label>2</label>
. Efficacy Over Time<lb/> 100<lb/> 80<lb/> 60<lb/> 40<lb/> 20<lb/> 0<lb/> Proportion of patients, %<lb/> Week<lb/> EASI75<lb/> A<lb/> 0<lb/> a<lb/> 1<lb/> a<lb/> 2<lb/> a<lb/> 4<lb/> a<lb/> 8<lb/> a<lb/> 12<lb/> a<lb/> 16<lb/> b<lb/> Upadacitinib (n = 348)<lb/> Dupilumab (n = 344)<lb/> 100<lb/> 80<lb/> 60<lb/> 40<lb/> 20<lb/> 0<lb/> Proportion of patients, %<lb/> Week<lb/> EASI90<lb/> B<lb/> 0 1<lb/> c<lb/> 2<lb/> a<lb/> 4<lb/> a<lb/> 8<lb/> a<lb/> 12<lb/> a<lb/> 16<lb/> a<lb/> Upadacitinib (n = 348)<lb/> Dupilumab (n = 344)<lb/> 100<lb/> 80<lb/> 60<lb/> 40<lb/> 20<lb/> 0<lb/> Proportion of patients, %<lb/> Week<lb/> EASI100<lb/> C<lb/> 0 1 2<lb/> 4<lb/> a<lb/> 8<lb/> a<lb/> 12<lb/> a<lb/> 16<lb/> a<lb/> Upadacitinib (n = 348)<lb/> Dupilumab (n = 344)<lb/> 0<lb/> -20<lb/> -40<lb/> -60<lb/> -80<lb/> -100<lb/> Change from baseline, %<lb/> Week<lb/> Worst pruritus NRS<lb/> D<lb/> 0<lb/> 2<lb/> a<lb/> 4<lb/> a<lb/> 6<lb/> a<lb/> 8<lb/> a<lb/> 12<lb/> a<lb/> 10<lb/> a<lb/> 14<lb/> a<lb/> a<lb/> a<lb/> a<lb/> a<lb/> a<lb/> a<lb/> a<lb/> a<lb/> 16<lb/> a<lb/> Upadacitinib (n = 348)<lb/> Dupilumab (n = 344)<lb/> A, Proportion </content>
 
            <figDesc>of patients achieving 75% improvement in Eczema Area and<lb/> Severity Index (EASI75) B, Proportion of patients achieving 90% improvement<lb/> in EASI (EASI90). C Proportion of patients achieving 100% improvement in<lb/> EASI (EASI100). D, Mean percentage change in Worst Pruritus Numerical Rating<lb/> Scale (NRS) for patients treated with upadacitinib or dupilumab by<lb/> nonresponder imputation incorporating multiple imputation to handle missing<lb/> data due to COVID-19. Error bars indicate 95% CIs (synthetic result based on t<lb/> test distribution from the PROC MIANALYZE procedure in SAS if there were<lb/> missing data due to COVID-19 or was based on the normal approximation to the<lb/> binomial distribution if there were no missing data due to COVID-19).<lb/> a P Յ .001.<lb/> b P Յ .01.<lb/> c P Յ .05.</figDesc>
        </figure>



    </text>
</tei>

